We thank Micheal Guirguis for his valuable comments on our paper.1 One of the limitations of our work, which we discussed in the article, was that we did not assay the active metabolite of clopidogrel directly but, rather, performed a platelet aggregation test with adenosine diphosphate as an indirect marker of the active clopidogrel metabolite, as done by previous investigators. Therefore, we were not able to rule out the involvement of factors other than the interaction of the active metabolite and the platelet adenosine diphosphate receptor.

We agree with Guirguis that pharmacokinetic–pharmacodynamic data are needed to confirm individual variations in clopidogrel metabolism. However, such data have not yet been collected because of the difficulty in assaying the active metabolite of clopidogrel. Some researchers are investigating clopidogrel metabolism using various methods,2–4 and we are looking forward to applying their findings to clinical studies in the near future.

We appreciate the suggestion by Craig McLachlan and associates of the possibility of rebound atherothrombotic events after cessation of clopidogrel administration in susceptible people, such as those with the non-expressor genotype for the 3A5 isoenzyme of the cytochrome P450 3A system. In our study, patients in the non-expressor group experienced more atherothrombotic events than those in the expressor group, and events after 1 month occurred only in the non-expressor group. However, all patients who experienced atherothrombotic events after 1 month were taking both clopidogrel and ASA at the time. Therefore, our data cannot be used to address the issue of whether people with the non-expressor genotype for the 3A5 isoenzyme of the cytochrome P450 3A system may be more vulnerable to atherothrombotic events after cessation of clopidogrel administration. However, it is possible that these patients are more sensitive to rebound effects on platelet aggregation in the setting of inhibition of the CYP3A4 isoenzyme. The issue raised by McLachlan and associates is an important one and warrants further study.

Jung-Won Suh
Bon-Kwon Koo
Hyo-Soo Kim
Department of Internal Medicine
Seoul National University College of Medicine
Seoul, Korea

REFERENCES

1. Sulb PW, Koo BK, Zhang SY, et al. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ 2006;174:1715-22.
2. Toubert D, Kastrati A, Hartinger S, et al. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost 2004;92:311-6.
3. Kaczenska H, Rudzki P, Bielowska-Kliszek M. Determination of clopidogrel metabolite (SR26334) in human plasma by LC-MS. J Pharm Biomed Anal 2006;41:533-9.
4. Souri E, Jalalzadeh H, Kebrizae-Zadeh A, et al. Validated HPLC method for determination of carboxylic acid metabolite of clopidogrel in human plasma and its application to a pharmacokinetic study. Biomed Chromatogr 2006;20:1309-14.
5. Toubert D, Kastrati A, Hartinger S, et al. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost 2004;92:311-6.
6. Sulb PW, Koo BK, Zhang SY, et al. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ 2006;174:1715-22.
7. Kaczenska H, Rudzki P, Bielowska-Kliszek M. Determination of clopidogrel metabolite (SR26334) in human plasma by LC-MS. J Pharm Biomed Anal 2006;41:533-9.
8. Souri E, Jalalzadeh H, Kebrizae-Zadeh A, et al. Validated HPLC method for determination of carboxylic acid metabolite of clopidogrel in human plasma and its application to a pharmacokinetic study. Biomed Chromatogr 2006;20:1309-14.

Driving and dementia

As a result of the work of Nathan Herrmann and colleagues1 we now have an improved understanding of the factors involved in driving cessation among people with dementia. Of particular interest was the finding that living in a jurisdiction with mandatory reporting did not significantly increase the risk of driving cessation. This leads one to question the utility of mandatory reporting, which may deter patients with dementia from relaying concerns about deterioration in their level of functioning to their physician.

Perhaps we are missing a more important issue associated with driving cessation if we focus unduly on safety rather than on mobility. Driving cessation is associated with significant difficulty in accessing services2 and is an independent risk factor for entry to a nursing home.3 Easy access to transportation is a key factor in maintaining the health and independence of older people and promotes social inclusion.4,5

Concern has been expressed that older people are discriminated against in public discussions about driving and health because of the emphasis on safety at the expense of a balanced perspective of the importance of both mobility and safety to health and social inclusion.6 As physicians, we need to be mindful of the enabling aspects of driving assessment (e.g., by an appropriate focus on arthritis, vision and medication review7), as well as the need to actively support other forms of facilitated transport (people who stop driving are usually not able to manage the rigours of public transportation).8 It is also important that any public health discourse support outdoor mobility and transportation for our patients.

Desmond O’Neill
Associate Professor
Department of Medical Gerontology
Trinity College
Dublin, Ireland

REFERENCES

1. Herrmann N, Rapport MJ, Sambrook R, et al; Canadian Outcomes Study in Dementia (COSID) Investigators. Predictors of driving cessation in mild-to-moderate dementia. CMAJ 2006;175:591-5.
2. Taylor BD, Tripodes S. The effects of driving cessation on the elderly with dementia and their caregivers. Accid Anal Prev 2001;33:519-28.
3. Freeman EE, Gange SJ, Munoz B, et al. Driving status and risk of entry into long-term care in older adults. Am J Public Health 2005;95:1254-9.
4. Final report of the White House Conference on Aging: 2005 Dec 11-14: Washington (DC). Washington (DC): US Department of Health and Social Services; 2006. Available: www.whcoa.gov (accessed 2006 Dec 5).
5. Organisation for Economic Co-operation and Development. Ageing and transport: mobility needs and safety issues. Paris: The Organisation; 2001.
6. Martin A, Balding L, O’Neill D. Are the media running elderly drivers off the road? BMJ 2005;330:368.
7. O’Neill D, Debbs B. Age-related disease, mobility and driving. In: Transportation in an aging society: a decade of experience. Transportation Research Board Conference Proceedings 27. Washington (DC): Transportation Research Board; 2004. p. 56-66.
8. Freund K. Independent transportation network: alternatives for the elderly. Transportation News 2000;206:3-12.